Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Benitec Biopharma (BNTC) Operating Expenses (2019 - 2025)

Benitec Biopharma (BNTC) has disclosed Operating Expenses for 7 consecutive years, with $17.2 million as the latest value for Q2 2025.

  • Quarterly Operating Expenses rose 209.59% to $17.2 million in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $38.9 million through Jun 2025, up 73.05% year-over-year, with the annual reading at $41.8 million for FY2025, 85.7% up from the prior year.
  • Operating Expenses hit $17.2 million in Q2 2025 for Benitec Biopharma, up from $5.1 million in the prior quarter.
  • In the past five years, Operating Expenses ranged from a high of $17.2 million in Q2 2025 to a low of $3.5 million in Q1 2022.
  • Historically, Operating Expenses has averaged $5.9 million across 5 years, with a median of $4.8 million in 2021.
  • Biggest five-year swings in Operating Expenses: fell 7.54% in 2022 and later surged 209.59% in 2025.
  • Year by year, Operating Expenses stood at $4.9 million in 2021, then rose by 15.72% to $5.6 million in 2022, then grew by 23.17% to $6.9 million in 2023, then skyrocketed by 55.98% to $10.8 million in 2024, then soared by 58.96% to $17.2 million in 2025.
  • Business Quant data shows Operating Expenses for BNTC at $17.2 million in Q2 2025, $5.1 million in Q1 2025, and $10.8 million in Q4 2024.